Ketamine Therapy Providers Sound the Alarm on Drug Shortages
Severe Depression Treatment Faces Setbacks
Limited Supply Hampers Critical Care
Ketamine therapy has emerged as a promising treatment for severe depression in recent years. However, a recent development has cast a shadow over the field: a shortage of ketamine hydrochloride injections, the primary ingredient used in therapy.
According to the FDA's website, ketamine hydrochloride injections are the only FDA-approved form of ketamine for use in treating depression.
An October 2023 survey conducted by ASKP3, an organization representing ketamine practitioners, revealed that 82% of the 126 respondents were facing ketamine shortages. The survey also indicated that these shortages were impacting their ability to provide adequate care to patients with severe depression.
The cause of the shortages is still under investigation, but it is believed to be linked to increased demand for ketamine therapy and potential supply chain issues.
The potential consequences of these shortages are significant. Patients with severe depression may lose access to a potentially life-saving treatment, and providers may be forced to reduce or discontinue services.
The ketamine therapy community is calling on policymakers and regulators to address this issue and ensure that patients continue to have access to this essential treatment option.
Original Article from Vice News on October 30, 2023: Ketamine Therapy Providers Say They're Running Out of...
Comments